23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
January 1994 in “Toxicological Sciences” Lower dosages of 2-(difluoromethyl)-dl-ornithine might reduce side effects, supporting further research.
6 citations
,
February 2009 in “Journal of Investigative Dermatology” 20 citations
,
August 1981 in “Developmental Medicine & Child Neurology” 13 citations
,
June 1981 in “Developmental Medicine & Child Neurology” 14 citations
,
February 1991 in “FEBS Letters” Introducing the rat OTC gene partially corrected OTC deficiency in mice.
November 2001 in “Oncology Times” The committee decided not to approve the drug due to low effectiveness and high risks.
July 2025 in “Reactions Weekly”
August 2009 in “Australian Prescriber” Dutasteride is approved to help manage prostate enlargement.
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
June 2023 in “International Journal of Pharmaceuticals Nutraceuticals and Cosmetic Science” New information shows Valproate may protect the brain and reduce breathing failure risk but can cause liver damage and other side effects, with genetics affecting dosage needs.
January 2024 in “Clinical and Experimental Dermatology” Baricitinib helps treat severe hair loss in people over 65.
January 2018 in “Journal of analytical, bioanalytical and separation techniques” 21 citations
,
January 2007 in “Journal of the European Academy of Dermatology and Venereology” Travoprost can help eyelash growth but may cause darkening around the eyes.
DiluCap improves how quickly minoxidil and finasteride dissolve and controls the release of melatonin and naltrexone.
1 citations
,
August 2022 in “JAAD case reports” Pioglitazone use was linked to hair regrowth in a patient with permanent hair loss from cicatricial alopecia.
20 citations
,
February 2017 in “European journal of pharmaceutical sciences” The MPA-ISO cocrystal improved solubility and dissolution rate, while the others did not.
1 citations
,
November 2011 in “British journal of pharmacology” Enzymes are classified into six types and are essential for many biological processes, with only a few targeted by drugs.
March 2008 in “British Journal of Pharmacology” Enzymes play crucial roles in metabolism, health, and disease management.
16 citations
,
March 2015 in “Clinical Cancer Research” The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
2 citations
,
November 2025 in “Pharmacology Research & Perspectives” Avacopan may cause unexpected side effects, so early monitoring is important.
9 citations
,
February 2012 in “Clinical Neurology and Neurosurgery” Dystonia may be part of PAS-4 and linked to immune issues.
February 2024 in “Journal of Cosmetic Dermatology” Using a laser with bimatoprost solution works better for hair regrowth in alopecia areata than bimatoprost alone.
23 citations
,
October 2021 in “AAPS PharmSciTech”
10 citations
,
January 2008 in “Acta dermato-venereologica” Carbamazepine caused hair loss and skin eruptions in a woman, which improved after stopping the medication.
47 citations
,
April 2017 in “European Journal of Pharmaceutics and Biopharmaceutics” The new dutasteride formula can be applied to the skin, may promote hair growth, and has fewer side effects.
1 citations
,
February 2025 in “Toxicology in Vitro” Diphlorethohydroxycarmalol may help treat hair loss better than current medications.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
18 citations
,
December 2016 in “European journal of pharmacology” A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.